Collaborations

Taiwan-based oncology-focused biotech company forms alliance with P&GP

Published in Cancer Weekly, February 8th, 2005

TaiGen Biotechnology announced the signing of a strategic alliance relationship with Procter & Gamble Pharmaceuticals (P&GP) to further the development and commercialization of a nonflourinated quinolone antibiotic, invented by P&GP.

Under the terms of the agreement, TaiGen will be responsible for conducting phase 1b and phase 2 development of the compound to meet worldwide regulatory standards.

If phase 2 results are positive, Procter & Gamble, in conjunction with TaiGen, may then seek a pharmaceutical partner for the phase 3 development and subsequent commercialization of the compound.

In addition, TaiGen acquires development...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-02-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry